{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fmyeloma-treatment-choices-faqs-_upEUHRH","width":444,"version":"1.0","type":"rich","title":"Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/1ce654be-9711-43fd-a9d0-0774d7ea7650/mm-rr-ss-asco-podcasticon-myeloma.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/df80d8f6-8117-4bc9-99dd-fc4b58f005bb\" height=\"200\" width=\"100%\" title=\"Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, as they answer audience questions from a live webinar about how to best use the plethora of active agents and regimens now available for patients with advanced multiple myeloma."}